Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer
NCT03830164
Erectile Dysfunction, Erectile Dysfunction, CTCAE
Houston, Texas, United States
View Trial DetailsNCT Number: NCT06798350
* Project Title**: Clinical Study on the Role of Inflammatory Markers in Patients with Erectile Dysfunction * Research Objective**:
To explore the changes in the levels of inflammatory markers in patients with erectile dysfunction (ED), providing scientific evidence for the diagnosis and treatment of ED.
**Study Design**: Retrospective controlled study
* Total Sample Size**:
150 cases * Case Selection**: * Inclusion Criteria for Case Group**:
1. Males with regular sexual activity; 2. Age between 18 and 55 years; 3. Complete medical records; 4. Completion of the International Index of Erectile Function-5 (IIEF-5), with IIEF-5 score < 22. Cases with an IIEF-5 score < 22 are diagnosed with ED, while the rest are diagnosed as non-ED. * Inclusion Criteria for Control Group**:
1. Males with regular sexual activity; 2. Age between 18 and 55 years; matched with the case group by age difference < 3 years. If multiple volunteers meet the criteria, the one closest in age to the case group is selected; 3. Complete medical records; 4. Completion of the International Index of Erectile Function-5 (IIEF-5), with IIEF-5 score ≥ 22. * Exclusion Criteria**:
1. Patients with spinal cord injury, neurological diseases, severe heart disease, or a history of penile fibrosis; 2. Patients undergoing treatment with phosphodiesterase type 5 inhibitors (PDE-5i); 3. Patients diagnosed with hormonal abnormalities, hyperthyroidism, hypothyroidism, Peyronie's disease, prostatitis, urethritis, or urinary tract infections; 4. Patients with poor rapid eye movement (REM) sleep quality. * Efficacy Assessment**: * Observational Indicators**:
Peripheral blood count, including monocyte count, neutrophil count, lymphocyte count, and biochemical markers such as C-reactive protein.
**Safety Evaluation Indicators**: Reproductive system damage.
**Statistical Methods**: Data analysis will be performed using R software (version 4.1.6). All statistical tests will be two-sided, with P values < 0.05 considered significant. Normality of data will be assessed using the Shapiro-Wilk test. Data with normal distribution will be presented as mean ± standard deviation, and data with non-normal distribution will be presented as median [interquartile range]. Baseline characteristics will be compared using independent sample t-tests, Mann-Whitney U tests, or chi-square/Fisher's exact tests. Multivariate analysis will be conducted using logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI). Missing data will be handled using appropriate methods based on the data missing mechanism. To control Type I errors, Bonferroni correction will be applied during multiple comparisons. All analysis procedures and code will be documented in detail to ensure the reproducibility of the analysis.
Trial opening soon.
Get Notified18 year and older
Male
Observational
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: A retrospective study observing patients approximately 1 month before and after diagnosis.
The diagnosis of ED is based on the IIEF-5 questionnaire score, with patients scoring <22 being diagnosed with ED, and the remaining patients being diagnosed as non-ED.
Contact information is provided by the study sponsor or research team.
Xijing Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03830164
Erectile Dysfunction, Erectile Dysfunction, CTCAE
Houston, Texas, United States
View Trial DetailsNCT07732387
Erectile Dysfunction, Erectile Dysfunctions
Herston, Queensland, Australia
View Trial DetailsNCT07719790
Cardiovascular Diseases, Erectile Dysfunction
Paris, France
View Trial DetailsNCT07685249
Erectile Dysfunction, Female Urogenital Diseases
Durham, North Carolina, United States
View Trial Details